血清磷酸吡哆醛水平与已确立的癫痫持续状态的相关性
该回顾性队列研究纳入2018年1月至2021年3月在两所医院临床诊疗中测定过血清PLP水平的住院和门诊患者共293例(eSE 52例、ICU无SE 40例、非ICU 44例、门诊157例),按首次PLP水平分为正常(> 30 nmol/L)、边缘性(≤ 30 nmol/L)、缺乏(≤ 20 nmol/L)和严重缺乏(≤ 5 nmol/L)。eSE组PLP中位数12 nmol/L,低于ICU无SE组22 nmol/L(p = 0.003)、非ICU组16 nmol/L(p = 0.05)和门诊组36 nmol/L(p < 0.001)。eSE组边缘性和缺乏PLP的患病率(分别为90%和80%)高于其他三组,校正危重程度和PLP采集时机后仍显著更高。作者认为需要开展吡哆醇补充治疗eSE患者的前瞻性研究。
要点
- eSE组血清PLP中位数12 nmol/L,低于ICU无SE组22 nmol/L(p = 0.003)、非ICU组16 nmol/L(p = 0.05)和门诊组36 nmol/L(p < 0.001)。
- eSE组边缘性(≤ 30 nmol/L)和缺乏(≤ 20 nmol/L)PLP患病率分别为90%和80%,高于ICU无SE组(70%、50%)、非ICU组(63%、54%)和门诊组(38%、21%)。
- 校正危重程度和PLP采集时机后,eSE组边缘性和缺乏PLP患病率仍显著高于其他三组。
- PLP分级标准:正常> 30 nmol/L、边缘性≤ 30 nmol/L、缺乏≤ 20 nmol/L、严重缺乏≤ 5 nmol/L。
- 作者认为,鉴于吡哆醇(PLP)在γ-氨基丁酸合成中的作用及其给药简便安全,需开展eSE患者吡哆醇补充的前瞻性研究。
适用人群与场景
- 2018年1月至2021年3月在University of North Carolina Hospitals和Yale New Haven Hospital临床诊疗中测定过血清PLP水平的住院和门诊患者。
- eSE组为已确立(苯二氮䓬类耐药)的癫痫持续状态患者;对照为ICU无SE患者、非ICU住院无SE患者、有或无癫痫史的门诊患者。
诊断标准与关键阈值
- 已确立的癫痫持续状态(eSE)定义为苯二氮䓬类耐药的癫痫持续状态。
- 血清PLP水平分级:正常> 30 nmol/L、边缘性≤ 30 nmol/L、缺乏≤ 20 nmol/L、严重缺乏≤ 5 nmol/L。
研究设计与关键结果
- 研究类型:回顾性队列研究,在University of North Carolina Hospitals和Yale New Haven Hospital开展,共纳入293例患者(eSE 52例、ICU无SE 40例、非ICU 44例、门诊157例),中位年龄55岁(范围19-99岁)。
- eSE组血清PLP中位数12 nmol/L,低于ICU无SE组22 nmol/L(p = 0.003)、非ICU组16 nmol/L(p = 0.05)和门诊组36 nmol/L(p < 0.001)。
- eSE组边缘性和缺乏PLP患病率分别为90%和80%,高于ICU无SE组(70%、50%)、非ICU组(63%、54%)和门诊组(38%、21%)。
- 校正危重程度和PLP采集时机后,eSE组边缘性和缺乏PLP患病率仍显著高于其他三组。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,鉴于吡哆醇(PLP)在γ-氨基丁酸合成中的作用及其给药简便安全,需开展eSE患者吡哆醇补充的前瞻性研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The objective of this study was to determine the prevalence of pyridoxine deficiency, measured by pyridoxal phosphate (PLP) levels, in patients admitted to the hospital with established (benzodiazepine-resistant) status epilepticus (SE) (eSE) and to compare to three control groups: intensive care unit (ICU) patients without SE (ICU-noSE), non-ICU inpatients without SE (non-ICU), and outpatients with or without a history of epilepsy (outpatient).
METHODS: This retrospective cohort study was conducted at the University of North Carolina Hospitals and Yale New Haven Hospital. Participants included inpatients and outpatients who had serum PLP levels measured during clinical care between January 2018 and March 2021. The first PLP level obtained was categorized as normal (> 30 nmol/L), marginal (≤ 30 nmol/L), deficient (≤ 20 nmol/L), and severely deficient (≤ 5 nmol/L).
RESULTS: A total of 293 patients were included (52 eSE, 40 ICU-noSE, 44 non-ICU, and 157 outpatient). The median age was 55 (range 19-99) years. The median PLP level of the eSE group (12 nmol/L) was lower than that of the ICU-noSE (22 nmol/L, p = 0.003), non-ICU (16 nmol/L, p = 0.05), and outpatient groups (36 nmol/L, p < 0.001). Patients with eSE had a significantly higher prevalence of marginal and deficient PLP levels (90 and 80%, respectively) than patients in each of the other three groups (ICU-noSE: 70, 50%; non-ICU: 63, 54%; outpatient: 38, 21%). This significantly higher prevalence persisted after correcting for critical illness severity and timing of PLP level collection.
CONCLUSIONS: Our study confirms previous findings indicating a high prevalence of pyridoxine deficiency (as measured by serum PLP levels) in patients with eSE, including when using a more restricted definition of pyridoxine deficiency. Prevalence is higher in patients with eSE than in patients in all three control groups (ICU-noSE, non-ICU, and outpatient). Considering the role of pyridoxine, thus PLP, in the synthesis of γ-aminobutyric acid and its easy and safe administration, prospective studies on pyridoxine supplementation in patients with eSE are needed.
参考来源
- Rubinos C, Bruzzone MJ, Blodgett C, et al. Association of Serum Pyridoxal Phosphate Levels with Established Status Epilepticus. Neurocrit Care. 2022. PMID: 36071331. doi:10.1007/s12028-022-01579-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。